LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants ...

ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients25 of 26 patients achieving CR remained in CR as of the data cut-offInitial data show the combination is generally well tolerated with a manageable safety profileCompany expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg doseCompany to host conference call ...

David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As an investor entrepreneur, David invests in stocks, bonds, options, ETFs, REITs, real estate, closed end funds and alternative investment funds such as hedge funds and private credit. With over 30 years’ experience in investing, David holds a Master of Science (MS) Degree in Finance, with a concentration in Investment Analysis, from Boston University, a Certificate in Financial Planning, and ...

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC TechnologyJune 09, 2025 3:15 AM EDT | Source: Defence Therapeutics Inc.Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance ...

核心观点 - 公司更新了IBI354在晚期实体瘤中的临床数据 该药物在多种肿瘤类型中显示出良好的抗肿瘤效果和安全性 验证了其ADC技术平台的优势 [1][2] - IBI354在铂耐药复发性卵巢癌和HER2阳性乳腺癌中表现出显著疗效 客观缓解率分别达到55%和59 1% 疾病控制率分别达到90%和90 9% [6][7] - 药物安全性优异 间质性肺病发生率仅1 9% 3级及以上治疗相关不良事件发生率为27 4% 无治疗相关死亡事件 [7] - 公司已启动IBI354在铂耐药卵巢癌的III期研究 并计划开展更多临床研究 推进下一代ADC分子的开发 [8] 临床数据 - 截至2025年3月24日 研究共纳入368例晚期实体瘤患者 中位随访时间11 5个月 中位治疗持续时间27周 20 1%患者仍在接受治疗 [3] - 在HER2阳性乳腺癌队列(n=88)中 确认客观缓解率59 1% 疾病控制率90 9% 9mg/kg Q3W亚组(n=29)客观缓解率高达72 4% 中位无进展生存期14 1个月 [7] - 在卵巢癌队列(n=92)中 确认客观缓解率41 2% 疾病控制率82 0% 12mg/kg Q3W亚组(n=40)客观缓解率55 0% 中位无进展生存期7 1个月 [7] 药物特性 - IBI354是公司自主研发的抗HER2抗体-喜树碱衍生物偶联物 药物抗体比(DAR)为8 具有高载药量 [9] - 采用高亲水性连接子设计 具有优异的生物物理和药代动力学特性 疏水性载荷增强了旁观者效应 [9] - 临床前和临床研究显示 该药物循环中游离毒素暴露极低 安全性理想 在多种肿瘤模型中显示出显著抗肿瘤活性 [9] 公司发展 - 公司专注于肿瘤 心血管代谢 自身免疫和眼科疾病领域的创新药物开发 已上市15款产品 [10] - 目前有3个新药申请在审评中 4个产品处于III期或关键临床试验阶段 15个分子在早期临床阶段 [10] - 公司与30多家全球医疗保健公司建立了合作关系 包括礼来 赛诺菲等 [10] - 公司持续推进ADC领域战略布局 展示在ADC药物开发方面的创新实力和技术优势 [8]

核心观点 - 信达生物(Innovent Biologics)在2025年ASCO年会上更新了其新型抗CLDN18 2 ADC药物IBI343治疗晚期胰腺癌的1期研究结果 该药物展现出显著疗效和良好安全性 并获得中国NMPA突破性疗法认定(BTD)及美国FDA快速通道资格(FTD) [1][2] - IBI343在CLDN18 2阳性晚期胰腺癌患者中显示出22 7%的客观缓解率(cORR)和81 8%的疾病控制率(DCR) 中位无进展生存期(mPFS)达5 4个月 中位总生存期(mOS)达9 1个月 [6] - 胰腺癌全球年新增病例约51万例 中国占12万例 该疾病5年生存率不足10% 现有化疗方案二线治疗有效率仅6-16% 临床需求迫切 [3][4] 药物研发进展 - IBI343采用Fc沉默抗体设计 稳定连接子和强效TOPO1i载荷 是首个在晚期胰腺癌中显示疗效和安全性的ADC候选药物 [4] - 截至2025年3月14日 83例胰腺癌患者接受IBI343治疗 中位随访11 1个月 安全性数据显示98 8%患者出现治疗相关不良事件(TEAEs) 但未发生≥3级恶心呕吐 [6] - IBI343通过CLDN18 2依赖性内化作用释放药物 产生DNA损伤和肿瘤细胞凋亡 并具有"旁观者杀伤效应" [7] 临床试验状态 - IBI343针对晚期胃癌/胃食管结合部腺癌的3期试验已启动患者招募 该适应症被纳入中国NMPA突破性疗法名单 [8] - 针对晚期胰腺导管腺癌的1期多区域研究正在进行 该适应症同时获得FDA快速通道和NMPA突破性疗法认定 [9] 公司概况 - 信达生物成立于2011年 已上市15款产品 另有3个新药申请在审 4个产品处于III期或关键临床试验阶段 15个分子在早期临床阶段 [10] - 公司与30多家全球医疗企业合作 包括礼来 赛诺菲等 专注于肿瘤 心血管代谢 自身免疫和眼科疾病领域创新药开发 [10]

Real estate is commonly perceived as a great investment to earn passive monthly income. Your tenants pay you rent checks each month, requiring little if any work from the landlord. That's at least the perception. In reality, we think ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed ...

REITs行业研究平台 - 公司推出iREIT®平台 提供房地产投资信托(REITs) 抵押贷款REITs(mREIT) 优先股 商业发展公司(BDCs) 业主有限合伙(MLPs) 交易所交易基金(ETFs) 建筑商和资产管理公司的深度研究服务 [1] - 平台包含iREIT® Tracker工具 覆盖超过250只证券 提供质量评分 买入目标和减持目标数据 [1] - 新增iREIT Buy Zone评级追踪器 帮助会员筛选价值标的 [2] 会员服务推广 - 提供2周免费试用机会 试用期间可获取完整研究服务 [2] - 免费试用包含赠书权益 [4]

The S&P 500 (^GSPC -0.01%) is offering a tiny 1.3% yield today. The average real estate investment trust (REIT) has a yield of around 4.1%.That's the backdrop for investors considering between net lease REIT Agree Realty (ADC 1.73%) and its average 4.1% yield, and Realty Income (O 0.48%) and its above-average 5.8% yield. But there's more than yield to examine in this matchup. What do Agree Realty and Realty Income do?At the core of the business models followed by Agree Realty and Realty Income are net lease ...